Haemonetics Corp (HAE)
82.75
+2.58
(+3.22%)
USD |
NYSE |
Mar 31, 16:00
82.83
+0.08
(+0.10%)
Pre-Market: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.175B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 30.89% |
| Valuation | |
| PE Ratio | 44.73 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.770 |
| Price to Book Value | 5.380 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.9881 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 68.62% |
News
Headline
Wire
Time (ET)
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/10/2023* | -- | Results | Q4 2023 | -- | -- | -- | |
| 05/10/2023* | 08:00 EST | Earnings Call | Q4 2023 | -- | -- | -- | |
| 02/07/2023 | -- | Results | Q3 2023 | 0.85 | 0.82 | 4.07% | |
| 02/07/2023 | 08:00 EST | Earnings Call | Q3 2023 | -- | -- | -- | |
| 11/07/2022 | -- | Results | Q2 2023 | 0.83 | 0.67 | 23.18% | |
| 11/07/2022 | 08:00 EST | Earnings Call | Q2 2023 | -- | -- | -- | |
| 08/10/2022 | -- | Results | Q1 2023 | 0.58 | 0.51 | 13.73% | |
| 08/10/2022 | 08:00 EST | Earnings Call | Q1 2023 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
| Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality. |
| URL | https://www.haemonetics.com |
| Investor Relations URL | https://haemonetics.gcs-web.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 10, 2023 (est.) |
| Last Earnings Release | Feb. 07, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 31, 2023.
Fundamentals
| Revenue (TTM) | 1.129B |
| Total Expenses (TTM) | 989.07M |
| Net Income (TTM) | 95.76M |
| Total Assets (Quarterly) | 1.878B |
| Total Liabilities (Quarterly) | 1.102B |
| Shareholders Equity (Quarterly) | 775.98M |
| Cash from Operations (TTM) | 261.50M |
| Cash from Investing (TTM) | -160.29M |
| Cash from Financing (TTM) | -107.53M |
Ratings
Profile
| Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality. |
| URL | https://www.haemonetics.com |
| Investor Relations URL | https://haemonetics.gcs-web.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 10, 2023 (est.) |
| Last Earnings Release | Feb. 07, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| HAE Tweets |